EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting the NO–sGC–cGMP Pathway: Mechanisms of Action of Vericiguat in Chronic Heart Failure

Tine Bajec, Gregor Poglajen iD

Cells · 08.09.2025 · 14 (17) · 1400

DOI: 10.3390/cells14171400 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 08.09.2025. Verfasst von Tine Bajec und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University Medical Centre, 1000 Ljubljana, Slovenia. Hauptthemen laut MEDLINE: Heart Failure, Soluble Guanylyl Cyclase, Cyclic GMP, Signal Transduction. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Slovenian Research and Innovation Agency, Slovenian Research and Innovation Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The recent advancements in the medical management of patients with chronic heart failure with reduced ejection fraction (HFrEF) is the soluble guanylate cyclase (sGC) stimulator, vericiguat. Clinical trials have demonstrated that vericiguat effectively lowers plasma levels of NT-proBNP and reduces the risk of cardiovascular death or hospitalization in HFrEF patients, making it a class IIb recommendation for patients with worsening heart failure despite receiving guideline-directed medical therapy. However, the precise pathophysiological mechanisms underlying these clinical benefits remain unexplored. This review aims to present the signalling pathways associated with maladaptive remodeling and heart failure progression that can be modulated by sGC stimulators, focusing on the antihypertrophic, antifibrotic, and anti-inflammatory effects of NO–sGC–cGMP signalling observed in preclinical studies. A better understanding of the mechanisms of action of sGC stimulators could optimize heart failure treatment strategies and enable tailoring of therapies to individual patient profiles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureSoluble Guanylyl CyclaseCyclic GMPSignal TransductionNitric OxidePyrimidinesHumansAnimalsChronic DiseaseHeterocyclic Compounds, 2-Ring

Stichwörter der Autor:innen

heart failuresoluble guanylate cyclase stimulatorsvericiguat

Substanzen

Soluble Guanylyl CyclaseCyclic GMPNitric OxidevericiguatPyrimidinesHeterocyclic Compounds, 2-Ring

Autor:innen und Institutionen

  • Department of Internal Medicine, University Medical Centre, 1000 Ljubljana, Slovenia.
  • Advanced Heart Failure and Transplantation Center, Department of Cardiology, University Medical Centre, 1000 Ljubljana, Slovenia.

ORCID-Profile: Gregor Poglajen

Förderung

  • The Slovenian Research and Innovation Agency
  • Slovenian Research and Innovation Agency

Zitieren

APA

Bajec, T., & Poglajen, G. (2025). Targeting the NO–sGC–cGMP Pathway: Mechanisms of Action of Vericiguat in Chronic Heart Failure. Cells, 14(17), 1400. https://doi.org/10.3390/cells14171400

Vancouver

Bajec T, Poglajen G. Targeting the NO–sGC–cGMP Pathway: Mechanisms of Action of Vericiguat in Chronic Heart Failure. Cells. 2025;14(17):1400. doi:10.3390/cells14171400

BibTeX
@article{Bajec2025,
  author = {Bajec, Tine and Poglajen, Gregor},
  title = {Targeting the NO–sGC–cGMP Pathway: Mechanisms of Action of Vericiguat in Chronic Heart Failure},
  journal = {Cells},
  year = {2025},
  volume = {14},
  number = {17},
  pages = {1400},
  doi = {10.3390/cells14171400}
}
Kostenlos starten →